Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.57 |
| ▸ | MAOA | P21397 | 10/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953529 | 1.00 | MAOB (0.57) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL30737401 | 0.85 | MAOB (0.49) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL29956503 | 0.83 | MAOA (0.54) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL2277043 | 0.83 | MAOA (0.57) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL28423025 | 0.82 | GSTP1 (0.44) | MAOBMAOACA12CA9CA2 | |
| SCHEMBL23315105 | 0.81 | CA12 (0.54) | MAOBMAOARAB9ACA12CA9 | |
| SCHEMBL13338101 | 0.81 | MAOB (0.59) | MAOBMAOACA12CA9CA2 | |
| SCHEMBL24215088 | 0.80 | MAOA (0.54) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL29954271 | 0.80 | MAOA (0.54) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL24215090 | 0.80 | MAOA (0.54) | MAOBMAOANPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2020-08-27 | — | — | US | disclosed |
| CN-111187279-A | Glaucocalyxin A-biotin small molecular probe and preparation method and application thereof | 新乡医学院 | 2020-05-22 | — | — | CN | disclosed |
| EP-3557998-A1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-8680265-B2 | Process for the preparation of a boron-substituted porphyrin | PSIMEI Pharmaceuticals (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680265-B2 | Process for the preparation of a boron-substituted porphyrin | PSIMEI Pharmaceuticals (GB) | 2014-03-25 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20100016613-A1 | PROCESS FOR THE PREPARATION OF A BORON-SUBSTITUTED PORPHYRIN | PSIMEI PHARMACEUTICALS PLC (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016613-A1 | PROCESS FOR THE PREPARATION OF A BORON-SUBSTITUTED PORPHYRIN | PSIMEI PHARMACEUTICALS PLC (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1671961-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6150404-A | IN SPECIFIED INSECTS, BY EXPOSING THE INSECTS TO FENFLUTHRIN OR CIS, 1R-METHYLENEDIOXYPHENYL-3-(2,2-DIHALOVINYL)-2,2 -DIMETHYLCYCLOPROPANECARBOXYLATE; WHERE METABOLIC MECHANISM OF RESISTANCE IS RESPONSIBLE IF A LARGE PERCENT OF INSECTS DIE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0072926-B1 | 2-ARYLIMIDAZOPYRIDINES | MERCK PATENT GmbH (DE) | 1986-09-24 | — | — | EP | disclosed |
| EP-0072926-A1 | 2-Arylimidazopyridines | MERCK PATENT GmbH (DE) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | MAOB 2648/4885MAOA 3243/4885NPC1 287/4885 |
| US-20100016613-A1 | PROCESS FOR THE PREPARATION OF A BORON-SUBSTITUTED PORPHYRIN | SCO2, PPOX, CNOT9 | MAOB 1963/4885MAOA 3944/4885NPC1 19/4885 |
| US-20200270211-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | MAOB 2648/4885MAOA 3243/4885NPC1 287/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | MAOB 2648/4885MAOA 3243/4885NPC1 287/4885 |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | NMT2, NAPRT, NAMPT | MAOB 1794/4885MAOA 1540/4885NPC1 3167/4885 |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | NPC1, CES2, CYP51A1 | MAOB 2665/4885MAOA 2568/4885NPC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.